Status:
COMPLETED
18F-Fluorocholine for the Detection of Parathyroid Adenomas
Lead Sponsor:
Thomas Hope
Conditions:
Hyperparathyroidism, Primary
Eligibility:
All Genders
13+ years
Phase:
PHASE2
PHASE3
Brief Summary
The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.
Eligibility Criteria
Inclusion
- Biochemically proven hyperparathyroidism and an indication for surgery
- Age \>= 13 years old
- Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).
- Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion
- Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.
- Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).
- Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).
- Pregnancy.
Key Trial Info
Start Date :
September 21 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03764007
Start Date
September 21 2016
End Date
May 31 2021
Last Update
October 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143